EQRx, Inc. (EQRXW) NASDAQ

0.05

+0(+0.00%)

Updated at January 16 04:00PM

Currency In USD

EQRx, Inc.

Address

50 Hampshire Street

Cambridge, MA 02139

United States of America

Phone

617 315 2255

Sector

Healthcare

Industry

Biotechnology

Employees

216

First IPO Date

December 20, 2021

Key Executives

N/A

Description

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.